Matthew Phipps
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
5
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NCNA NuCana | Downgrades: Market Perform | n/a | $1.55 | - | 1 | Aug 30, 2024 | |
| AMGN Amgen | Upgrades: Outperform | n/a | $316.91 | - | 1 | May 3, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Outperform | n/a | $18.03 | - | 1 | Dec 19, 2022 | |
| IKNA Ikena Oncology | Initiates: Outperform | n/a | $1.72 | - | 1 | Apr 20, 2021 | |
| PIRS Pieris Pharmaceuticals | Initiates: Outperform | n/a | $16.98 | - | 1 | Jan 17, 2018 |
NuCana
Aug 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.55
Upside: -
Amgen
May 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $316.91
Upside: -
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Outperform
Price Target: n/a
Current: $18.03
Upside: -
Ikena Oncology
Apr 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.72
Upside: -
Pieris Pharmaceuticals
Jan 17, 2018
Initiates: Outperform
Price Target: n/a
Current: $16.98
Upside: -